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Traumatic brain injury (TBI)-related hypopituitarism has been recognized as a clinical entity
for more than a century, with the first case being reported in 1918. However, during the
20th century hypopituitarism was considered only a rare sequela of TBI. Since 2000
several studies strongly suggest that TBI-mediated pituitary hormones deficiency may be
more frequent than previously thought. Growth hormone deficiency (GHD) is the most
common abnormality, followed by hypogonadism, hypothyroidism, hypocortisolism, and
diabetes insipidus. The pathophysiological mechanisms underlying pituitary damage in
TBI patients include a primary injury that may lead to the direct trauma of the
hypothalamus or pituitary gland; on the other hand, secondary injuries are mainly
related to an interplay of a complex and ongoing cascade of specific molecular/
biochemical events. The available data describe the importance of GHD after TBI and
its influence in promoting neurocognitive and behavioral deficits. The poor outcomes that
are seen with long standing GHD in post TBI patients could be improved by GH treatment,
but to date literature data on the possible beneficial effects of GH replacement therapy in
post-TBI GHD patients are currently scarce and fragmented. More studies are needed to
further characterize this clinical syndrome with the purpose of establishing appropriate
standards of care. The purpose of this review is to summarize the current state of
knowledge about post-traumatic GH deficiency.
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Traumatic brain injury (TBI) is one of the leading causes of disability and mortality affecting many
people each year and resulting in a serious burden of devastating health consequences (1–3). The
most common mechanism for TBI are falls, especially in older adults and very young children;
motor vehicle accidents are instead the most frequent cause of TBI among young adults (1). TBI
may lead to permanent or transient pituitary insufficiency (4, 5). The clinical picture presents a very
large spectrum determined by the kind, number and severity of hormonal deficiency and could gon.org March 2021 | Volume 12 | Article 6344151
Gasco et al. TBI and GHD: An Overviewfrom mild and non-specific complaints to life-threatening
conditions. The reported prevalence of hypopituitarism is quite
variable among the available studies (6–9). The pathophysiologic
mechanisms underlying pituitary damage in TBI patients include
a primary injury that may lead to direct trauma to the
hypothalamus or pituitary gland, or to compressive effect from
surrounding structures; secondary injuries, on the other hand,
are mainly related to an interplay of a complex and ongoing
cascade of specific molecular/biochemical events. The diagnosis
of pituitary dysfunction is very challenging both due to the
common occurrence of TBI, the subtle character of clinical
manifestations, the variable course of the disease, as well as the
lack of proper diagnostic algorithms. Growth hormone
deficiency (GHD) is the most common abnormality, followed
by hypogonadism, hypothyroidism, hypocortisolism, and
diabetes insipidus (8, 9). The purpose of this review is to
summarize the current state of knowledge about post-
traumatic hypopituitarism, and especially about post-traumatic
GHD. However, well-designed studies are needed to further
investigate the pathophysiology, epidemiology, and timing of
pituitary dysfunction after a TBI with the purpose of establishing
appropriate standards of care.EPIDEMIOLOGY OF TBI AND
TBI-RELATED HYPOPITUITARISM
Epidemiology of TBI
TBI is one of the leading causes of disability and mortality in
western countries. It can be estimated that in the United States,
every year there are around 2.5 million visits at the emergency
department, 280,000 hospitalizations and 50,000 deaths related
to TBI (1).
The highest rates of TBI are observed in older adults (≥75
years; 2232 per 100,000 population), followed by very young
children (0 to 4 years; 1591 per 100,000) and young adults (15 to
24 years; 1081 per 100,000). There is a sex prevalence, with males
showing a higher risk than females (959 per 100,000 vs 811 per
100,000). Falls are the most common mechanism for TBI,
especially in older adults and very young children; motor
vehicle accidents are instead the most frequent cause of TBI
among young adults (1).
After the acute phase, TBI-survivors are often forced to deal
with relevant and persistent long-term sequelae, with significant
neurological and functional impairment. The prevalence of TBI-
related long-term disability in the United States is estimated to
affect between 3 and 6 million patients, i.e., 1% to 2% of the
population (2, 3).
Apart from the individual sequelae, TBI clearly determines
significant economic implications for society, related both to
direct expenses for medical care and to indirect costs caused by
injury-related work loss and disability (10). The former can be as
high as 80,000 US dollars per person in the first year after trauma
(11). The latter is more difficult to estimate, but it is likely to
account for more than 80% of the total economic burden of
TBI (10).Frontiers in Endocrinology | www.frontiersin.org 2Epidemiology of TBI-Related
Hypopituitarism
TBI-related hypopituitarism has been recognized as a clinical
entity for more than a century, with the first case being reported
in 1918 (12). However, during the 20th century it was considered
only a rare sequela of TBI.
Most likely, hypopituitarism was under-recognized for such a
long time for its generally subtle and nonspecific clinical features
that also share a significant overlap with many of the somatic,
psychiatric and neurological symptoms directly related to TBI.
As a consequence, only patients with the frankest clinical
pictures were probably identified as having a TBI-related
hypopituitarism, leaving unrecognised the vast majority of TBI
patients with some degree of pituitary deficits. This
underestimation may probably have affected patient life
expectancy and quality, as it happens to every patient living
with unrecognised and untreated hypopituitarism (13).
The awareness of the critical relevance of hypopituitarism in
TBI patients radically changed during the last two decades. The
first two cornerstone studies that solidly proved that TBI-related
hypopituitarism was a far more common sequela of head trauma
than previously thought have been published in 2000 and 2001
(4, 5). Since then, several other studies of the endocrine function
in patients after TBI have been published (6, 7, 14–40).
The reported prevalence of hypopituitarism is quite variable
among the available studies, ranging from 1% (6) to 76% (7).
However, this relevant heterogeneity should not surprise because
the existing studies widely differ in many aspects, such as study
design, age of patients, severity of trauma, time point of
endocrinological evaluation and testing protocols for the
diagnosis of the deficiency of the various pituitary axes.
Given these premises, an overall summary of the available
evidence can be found in two major meta-analyses (8, 9). Pooled
data show that the proportion of patients with some kind of
pituitary disfunction can be estimated to be approximately 27.5-
32.0% (8, 9). In most individuals only a single pituitary axis is
affected (19.8-25.3%) (8, 9), while involvement of multiple
pituitary axes is far less frequent (6.7-7.7%) (8, 9).
Furthermore, it has been consistently proved that not all
pituitary axes are equally susceptible to TBI-mediated damage.
The most sensitive ones appear to be GH and FSH/LH (12.4-
22.1% and 10.2-12.5%, respectively) (8, 9); on the other hand,
deficits of ACTH and TSH axes appear to be significantly less
frequent (8.2-9.9% and 4.1-6.2%, respectively) (8, 9).PATHOPHYSIOLOGY OF TBI-RELATED
HYPOPITUITARISM
Overview on the Pathophysiology of TBI
TBI is a heterogeneous disease. There are many ways to
categorize the patients, both in terms of clinical severity and
pathophysiological mechanism of injury.
Clinical severity is usually assessed by specific severity scores;
the most commonly used is the Glasgow Coma Scale (GCS),
which evaluates three neurological domains (eye opening, bestMarch 2021 | Volume 12 | Article 634415
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(GCS 13-15), moderate (GCS 9-12) or severe (GCS ≤ 8) (41).
The pathophysiology of TBI is usually summarized into two
separate categories: primary and secondary brain injury (42).
Primary brain injury occurs at the time of trauma, as a
consequence of external mechanical forces transferred to
intracranial content. The pathologic sequelae of primary brain
injury include shearing of white matter tracts (also known as
diffuse axonal injury), focal cerebral contusion/hemorrhages, and
focal extra-axial hematomas/hemorrhages (i.e. epidural
hematomas, subdural hematomas, subarachnoid hemorrhage
and intraventricular hemorrhage) (42, 43).
Following this primary injury, extensive and lasting damage is
sustained through a complex and ongoing cascade of events
referred to as secondary brain injury. Pathogenesis is driven by
complex, interacting mechanisms that include, among others,
neurotransmitter-mediated excitotoxicity, secondary ischemia
(from vasospasm or other secondary vascular injuries, such as
focal microvascular occlusion), and inflammatory responses. As
a final consequence, these mechanisms of injury lead to neuronal
cell death, cerebral edema and increased intracranial pressure,
which can further exacerbate brain damage (42, 44, 45).
Pathophysiology of TBI-Related
Hypopituitarism
From a general point of view, the pathophysiological
mechanisms underlying pituitary damage in TBI-patients are
broadly similar to those described for TBI itself.
Primary injury may lead to direct trauma of the
hypothalamus or pituitary gland, or to compressive effect from
surrounding structures (42, 43); moreover, especially in case of
skull base fracture, primary injury may determine pituitary stalk
transection (46) (Figure 1).
On the other hand, secondary injuries are mainly related to an
interplay of a complex and ongoing cascade of specific
molecular/biochemical events (42, 44, 45) (Figure 1).Frontiers in Endocrinology | www.frontiersin.org 3As already discussed, one of the three major mechanisms for
secondary brain injury after head trauma is represented by
excitotoxicity. Excitotoxicity is caused by the abnormal levels
of excitatory neurotransmitters (mostly glutamate) that are
uncontrollably released in patients with TBI. In fact, at high
concentrations, these neurotransmitters act as excitotoxins,
operating on ion channels and thus altering cell wall
permeability with an unregulated electrolyte shift between
intra- and extracellular spaces (47).
Another mechanism for secondary brain damage after TBI is
represented by ischemia. Overall, the same pathophysiological
events affecting brain are likely to underlie the pituitary-specific
ischemic insult as well. However, some distinctive points related
to the peculiar vascularization of the hypothalamic-pituitary area
are still worth to be discussed. As known, the anterior pituitary
receives its blood supply from the hypothalamic-hypophyseal
portal circulation (48–50), which likely poses the gland to a
greater risk of ischemic harm (Figure 2). In particular, long
hypophyseal portal vessels substantially represent the only
source of vascularization of the lateral portion and of pars
tuberalis (mostly populated by GH, PRL and FSH/LH secreting
cells) (52) (Figure 3). Instead, the antero-medial portion and the
central wedge (mostly populated by TSH and ACTH secreting
cells) (52) (Figure 3) receive a mixed supply by both long and
short hypophyseal portal vessels (48–50) (Figure 2). Therefore,
the ischemic susceptibility hypothesis may be one of the most
plausible explanation for the differential frequency of pituitary
axes involvement after TBI. In fact, the most vulnerable axes (GH
and FSH/LH) are those whose blood supply only relies on long
hypophyseal portal vessels, that are by themselves more prone to
vascular damage; instead, the most resilient ones (ACTH and
TSH) are those whose blood supply is guaranteed both by long
and short hypophyseal portal vessels (48–50, 52) (Figures 2, 3).
The third and last major mechanism implied in the
pathophysiology of secondary pituitary injury after trauma is
inflammation. Part of the inflammation mechanisms affectingFIGURE 1 | Main pathophysiological mechanisms underlying pituitary damage after TBI. TBI, traumatic brain injury; AHA, anti-hypothalamus antibodies; APA, anti-
pituitary antibodies.March 2021 | Volume 12 | Article 634415
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inflammation mechanisms known to affect the brain
parenchyma as a whole, with an uncontrolled and self-
sustaining release of pro-inflammatory cytokines such as
interleukin 1 (IL-1) and tumor necrosis factor a (TNF-a) (53).
In addition, a pituitary-specific inflammatory mechanism
may be related to autoimmunity and, more specifically, to the
presence of anti-hypothalamus antibodies (AHA) and/or anti-
pituitary antibodies (APA). The positivity to these antibodies was
demonstrated to be more frequent in patients with previous TBI
(ranging from 44% to 60% depending on the study) than in
matched healthy controls (0%) (54, 55). A similar result, even if
less pronounced, was found in a cohort of subjects who
underwent chronic repetitive head trauma due to amateur
boxing activity, in which a higher positivity of AHA (21%) and
APA (23%) was found compared to matched controls (0%) (56).
Moreover, among patients with previous TBI, various authors
have demonstrated a statistically significant correlation between
the presence of AHA and/or APA positivity and that of post-
traumatic hypopituitarism, with an odds-ratio (OR) ranging
from 2.2 to 8.5, depending on the study (54–56). Looking at
the whole body of these results, it is therefore reasonable to
hypothesize that autoimmunity may play a role in the
pathogenesis of TBI-induced hypopituitarism. The genesis of
AHA and/or APA production is likely related to hypothalamus
and/or pituitary exposure and release of antigens that would have
otherwise remained unexposed. Despite the aforementioned
association, the available evidence is not clearly sufficient to
establish whether AHA/APA positivity may actually play an
active pathophysiological role in the propagation/perpetuation of
TBI-related pituitary damage, or may instead represent only an
epiphenomenon of hypothalamic/pituitary antigen exposure due
to necrotic post-TBI alterations of these areas.
Finally, another potential pituitary-specific inflammatory
modulation mechanism may be related to individual intrinsic
genetic susceptibility. In the general context of traumatic brain
injury, ApoE polymorphisms have been widely shown to be
associated with various clinical outcomes after TBI, such as the
onset of seizures (57), coma duration (58), and subsequent
neurobehavioral recovery (59). In fact, ApoE is a key protein
in enhancing lipid transport and metabolism within the nervous
system and has a role in neuronal repair and maintenance. In the
specific context of post-traumatic hypopituitarism, a study from
Tanriverdi et al. confirmed the possible role of ApoE
polymorphism on neuroendocrinological outcomes; in
particular, this study demonstrated a likely protective role of
ApoE3/E3 genotype against the development of post-traumatic
pituitary disfunction, with an estimated OR of 0.29 (60).
Evidence From Histopathological Studies
Most histopathological studies in patients with TBI-related
hypopituitarism have been published several decades ago, as
autoptic case series. These studies showed that the most frequent
pathological alterations of pituitary gland after TBI were anterior
lobe ischemic necrosis, posterior lobe haemorrhage and pituitary
stalk haemorrhage, each occurring in approximately 14-42% of
patients (61–64). A normal pituitary could be found in a variableFrontiers in Endocrinology | www.frontiersin.org 5proportion of 14-74% of patients, depending on the study
(61–64).
More recently, another study by Salehi et al. (65) provided a
further insight into histopathological changes of the pituitary
gland after TBI. The overall results were not in contrast with
previous case series, but a more accurate analysis relating
pathological findings to the timing of death after trauma has to
be discussed. In fact, the authors showed that no abnormalities of
the pituitary gland could be found in patients who died
immediately after trauma, both at macroscopic and at
microscopic level. On the other hand, several degrees of
pituitary haemorrhage and/or ischemic necrosis could be found
in 43% of patients who survived between 3 h and 7 days after
trauma. Moreover, the extent of histopathological alterations in
those patients was significantly related to the time elapsed between
injury and death (< 10% of adenohypophysis involved in patients
who died within 1 day, > 50% in patients who died between 1 and
7 days) (65).
In conclusion, the whole body of histopathological evidences
supports the hypothesis that post-TBI neuroendocrine damage
could be mostly related to pituitary vascular vulnerability.
However, despite the interest of these results, it must be
pointed out that they are based on autoptic studies looking at a
very specific and selected subset of TBI patients, i.e. those dying
in the acute phase after a severe TBI. This undoubtedly
represents an important selection bias, as this category of
patients accounts for just a small minority of all patients
suffering from TBI. Moreover, this is a category of TBI patients
in which correlation with hormonal outcomes is neither feasible
nor relevant. Precise pituitary histopathological correlations in
long-term TBI survivors are thus lacking, but further research in
this field are clearly conditioned by the constitutional limit to
conduct this kind of evaluation in vivo.
Evidence From Imaging Studies
Several studies have been published about the possible
identification of microstructural abnormalities of the pituitary
gland by imaging techniques in patients with TBI-related
hypopituitarism. Also in this subset of patients the imaging
modality of choice for the evaluation of the pituitary gland was
mostly MRI.
No single features were found to predict with high accuracy
the presence or the absence of hypopituitarism in patients
experiencing TBI. Therefore, in clinical practice the role of
imaging in the prediction of post-traumatic hypopituitarism is
limited. However, the available evidence is still of significant
interest, as it provides information on the possible
pathophysiological mechanisms through which post-traumatic
hypopituitarism develops.
In this regard, the role of imaging is surely less accurate than
that of pathological studies, considering that the deduced
evidences about the underlying pathophysiological mechanisms
can be only indirect. On the other hand, the clear advantage is
that these evidences may be obtained for all patients with TBI,
regardless of trauma severity and mortality.
In the acute phase, Maiya et al. (66) showed a significant
enlargement of pituitary gland dimensions after TBI comparedMarch 2021 | Volume 12 | Article 634415
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not only in those patients with focal changes of the pituitary
gland (haemorrhagic foci, heterogeneous signal intensities,
macroscopical swelling) but also in those without specific
focal pituitary abnormality. This is consistent with a
pathophysiological hypothesis of an underlying pituitary
edematous change, which is likely to be predominant in the
first days after TBI. However, in this study no data about the
subsequent pituitary functional outcomes were available, neither
in the short nor in the long term. Therefore, it is not possible –
based on these data – to explore the potential correlation of
pituitary dimension in the acute phase and the subsequent
development of pituitary deficits.
In the subacute phase, Zheng et al. (67) showed a reduction in
apparent diffusion coefficient (ADC) in diffusion-weighted
imaging (DWI) of pituitary gland in patients with previous
TBI compared to healthy controls. DWI is based on the
capacity of MRI to demonstrate the random, brownian
diffusion movement of water. It is widely recognized as one of
the best imaging modalities of cerebral ischemia, in which failure
of the energy-dependent Na-K-ATPase determines a
translocation of water from the interstitial to the intracellular
space, and therefore a reduction of its diffusion capacity (68).
This diffusion restriction determines a coherent change in signal
intensity on DWI and on the derived ADC map, in which
ischemic areas appear characteristically hypointense (69, 70).
The results obtained by Zheng et al. thus confirm the probable
role of ischemia in pituitary microstructural change in the first
few weeks after TBI. Interestingly, even if ADC reduction with
respect to healthy controls was found to be significant in the
whole cohort of TBI patients, this alteration resulted to be more
prominent in those which subsequently developed pituitary
deficits at the hormonal follow-up; this is a further proof of the
plausible relation between the severity of microstructural
ischemic abnormalities in the short-term and the final
functional outcome in the long-term.
In the chronic phase, Schneider et al. (71) showed that, after
TBI, pituitary abnormalities at imaging were more frequent in
patients with some degree of hypopituitarism (80%) than in
those without pituitary hormone deficits (29%). The most
common finding, in particular, was pituitary volume reduction,
up to the degree of empty sella in some patients. The
pathophysiological process underlying these changes is
plausibly related to the long-term sequelae of pituitary tissue
necrotization and subsequent fibrosis, which likely contribute to
irreversible tissue loss.
The evidence of a pituitary volume reduction in the chronic
phase finds further confirmation in a study by Tanriverdi et al.
(72), in which the authors examined pituitary function and
pituitary volume in a cohort of amateur boxers. As it is known,
boxers are exposed during their career to mild chronic repetitive
head traumas, which may determine pathophysiological
consequences similar to classical TBI in the long term. In this
study, 18% of boxers had some degree of pituitary dysfunction,
and the presence of one or more hormonal deficits was
significantly correlated with a lower pituitary volume at MRI.Frontiers in Endocrinology | www.frontiersin.org 6TBI-RELATED HYPOPITUITARISM:
CLINICAL PRESENTATION
Post-traumatic hypopituitarism (PTHP) can present with
variable and non-specific clinical features, which may overlap
with those resulting from the injury. The consequence is a delay
in diagnosis, with a higher morbidity and mortality (39).
The clinical picture presents a very large spectrum
determined by the kind, number and severity of hormonal
deficiencies and could go from mild and non-specific
complaints to life-threatening conditions (73).
Traditionally, an acute and a chronic phase can be
distinguished, but pituitary dysfunction during the acute phase
does not necessarily lead to long-term hypopituitarism. In a
systematic review, the analysis of prospective studies showed that
some of the early abnormalities are transient with complete
recovery, while hypopituitarism can evolve over time and
become detectable only later (8).
The first 2 weeks after trauma are considered the acute stage.
The most common hormonal changes in this phase are
represented by gonadotropin and GH deficiency, but in the
clinical presentation they are not the most evident.
In fact, the most fearsome endocrinological complication of
the acute stage is adrenal insufficiency. Hyponatremia,
hypoglycemia, hypotension, fatigue, mental confusion are some
of its typical features. Patients affected by hypocortisolism
require a higher dose of vasopressors and have a higher
mortality rate; therefore hormone replacement therapy is
crucial (74, 75).
Impaired vasopressin secretion (Syndrome of Inappropriate
Antidiuretic Hormone Hypersecretion - SIADH or Central
Diabetes Insipidus - CDI) could also be life-threatening,
contributing to the hydro-electrolytic imbalance of the acute
phase (76).
Hypothyroidism can be also reported, due to the adaptive
response after trauma and the use of steroids. It contributes to
the clinical picture of marked asthenia, lethargy and confusion,
not always easy to discriminate in the acute stage.
GHD is considered a common alteration of the acute phase,
reflecting the adaptive response after the traumatic event.
Hyperprolactinemia could be reported as a consequence of
pituitary stalk compression or as a physiological reaction to
stress. Together with hypogonadism, hyperprolactinemia may
lead to the menstrual alteration and the sexual dysfunction of the
post-TBI period.
Some of these abnormalities are transient: recovery from
hypoadrenalism is described in 50% of patients, from CDI in
up to 90% (77). Hypothyroidism and SIADH often resolve in 3-
12 months (40).
The chronic phase starts at 3 months after TBI. The clinical
features could be very variable and not specific, depending on the
different axes involved. Lethargy or insomnia, fatigue, reduced
attention, difficulty concentrating, memory impairment, anxiety,
depression, irritability anddiminished libido are oftendescribed (78).
Also in this phase GHD and hypogonadism are the most
frequent anomalies, hypocortisolism and central hypothyroidismMarch 2021 | Volume 12 | Article 634415
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patients (79).
These patients experience metabolic abnormalities,
neurocognitive impairment, and a decreased quality of life
(34, 80).
Metabolic Alterations
In patients with PTHP, altered function of hypothalamic nuclei
and pituitary disfunction itself determine an adverse metabolic
profile. Glycemic disorders, dyslipidemia, weight gain with
abdominal fat distribution, changes in body composition and
reduced bone mineral density determine the higher morbidity
and mortality of these patients (78).
Different studies demonstrated that PTHP patients have
higher BMI, increased LDL cholesterol and total cholesterol
(19), altered glucose levels and insulin resistence (34).
Decreased thyroid function reduces the basal metabolic rate
and hypogonadism affects bone and muscle mass, beyond the
effect on libido and reproduction. It is however GHD that plays
the major role, affecting glycemic and lipidic profile, increasing
BMI and waist circumference, reducing bone mineral density
and leading also to anemia (78).
GHD can affect also the rehabilitation: patients with post-TBI
GHD seem to have lower aerobic capacity, a measure of physical
resistance, which may delay or inhibit the recovery process (81).
Neurocognitive Alterations
Recently, more attention was paid to neuropsychiatric symptoms
which are due both to PTHP and brain injury itself. Cognitive
and affective impairment may be severe, prejudicing patients’
social skills. In fact, attention, memory, executive functions and
language can be involved.
Symptoms of PTHP can overlap with cognitive, sleep, mood,
and anxiety disorders due to Post-Traumatic Stress Disorder
(PTSD). Differential diagnosis can be challenging, but essential
for the therapeutic implications.
Hypothyroidism is associated with neurocognitive function:
low speed of information processing and deficits in short-term
memory are the most described (73).
Hypogonadism is also associated with cognitive dysfunction:
patients with lower testosterone levels after TBI seem to have an
increased risk for Alzheimer’s disease (82).
Also hypoadrenalism results in mood disorders, decreased
memory, and frank psychosis in the chronic phase, in addition to
the classical picture of fatigue, weakness, and impaired response
to stress (78).
Although every hypothalamic-pituitary axis could be involved
in cognitive functions, the role of GH and the effects of its
deficiency are the most known and frequently observed (83).
In fact, somatotropic axis has a role in microtubular
regeneration, dendritic growth and regrowth, regulation of the
use of glucose in the brain and, probably, an action on
hippocampal area. So, GHD may lead to impaired neuronal,
somatic, and dendritic growth, affecting memory and cognitive
function too (78, 84).
Several studies reported that patients with post-traumatic
GHD have more severe cognitive impairment, in particularFrontiers in Endocrinology | www.frontiersin.org 7deficit in attention and memory, as well as emotional
problems, than those with normal GH values (33, 85, 86).
Patients with post-TBI GHD have a higher risk to achieve
poor cognition outcomes than those with an intact somatotropic
axis after trauma (87). Park et al. showed that patients with GHD
after TBI have decreased cerebral glucose metabolism in specific
cortical areas involved in intellectual function, executive
function, and working memory (88).
In contrast to all these studies, Pavlovic et al. did not find
significant differences between patients with or without GHD
after brain injury (89).
Quality of Life (QoL)
Another important feature is QoL: patients with post-TBI GHD
are more likely to be depressed and with a poorer quality of life
than those with GHD due to other causes. In particular, domains
of physical health, energy and fatigue, emotional well-being,
pain, and general health seem to be affected (85).
Also perceived poor QoL would negatively impact on
rehabilitation after TBI.TBI-RELATED HYPOPITUITARISM:
DIAGNOSIS
PTHP, and in particular GHD, are often underdiagnosed:
patients with post-TBI GHD seem to be diagnosed on average
two and a half years later after the primary onset of disease when
compared to those with Non-Functioning Pituitary Adenoma
(NFPA) (87).
PTHP diagnosis is not different from hypopituitarism due to
other causes. However, the time and type of hormonal
assessment in TBI patients is controversial.
Who to Test
Despite the severity of trauma itself, hypopituitarism can develop
in patients post-TBI, but testing all of them is not feasible
because of the great amount of human and economic resources
needed. A rational approach is to evaluate life expectancy,
avoiding to test patients with poor prognosis who cannot
benefit of hormonal replacement therapy. Conversely, patients
with mild TBI could develop hypopituitarism, but not all of them
achieve medical attention (90) and testing is not considered cost-
effective (87).
Epidemiology could be useful to establish who to screen: in
fact, PTHP frequency is better established in patients with
moderate or severe TBI based on GCS score. Furthermore,
other risk factors include age, intracranial hemorrhage, focal
cortical contusion, seizures and skull base fracture.
In patients symptomatic for acute hypopituitarism (i.e.
electrolyte unbalance and/or acute adrenal insufficiency) an
endocrinological evaluation is mandatory.
Patients with mild TBI who need hospitalization (more than
24 h), a neurosurgical intervention, monitoring in an Intensive
Care Unit, or those who present anatomical changes on CT scan,
are considered complicated and screening is also recommended
(87). Conversely, patients with a mild uncomplicated TBI shouldMarch 2021 | Volume 12 | Article 634415
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present (91).
Patients who required hospitalization for at least 24 h, those
with radiological abnormalities on CT scan, and those who
presents signs and symptoms of PTHP should be screened at
three months and one year post-TBI. It is possible to perform
hormonal screening even further, if symptoms persist (78).
Biochemical Evaluation: Time and Kind
Pituitary function evaluation could be challenging in the acute
phase post-TBI. In fact, in this stage patients have hormonal
changes as part of the stress response and acute adaptive
response to injury. Hormonal levels are also affected by
medications and surgery. Pituitary function during this time
could be variable (78).
While some of the alterations are natural consequences of the
trauma itself, others are life-threatening and require an
immediate hormonal replacement therapy. So, basal hormonal
evaluation should be performed in any patient with TBI who has
been hospitalized and presents signs and symptoms suggesting
adrenal insufficiency (92). For the diagnosis, a morning serum
cortisol should be measured. Usually, a level beyond 15 µg/dL
indicates a proper function, values between 3 and 15 µg/dL
require further investigation using a stimulation test, while a
concentration lower than 3 µg/dL allows a diagnosis of
hypoadrenalism (93). In the post-TBI context, these cut-points
are not considered applicable. In fact, plasma cortisol
concentrations rise in parallel to the severity of acute illness, so
Hannon et al. proposed that critically sick patients should have
plasma cortisol levels >300 nmol/L (=10.875 µg/dL), suggesting
the need of hormonal replacement therapy for lower values (74).
Also the evaluation of cortisol reserve with a dynamic test seems
to be not reliable in TBI patients, at least in the acute phase. In
fact, Endocrine Society Clinical Practice Guidelines suggest
performing an ACTH stimulation test (Synacthen test) when
required for secondary adrenal deficiency diagnosis (93),
preferring the low-dose (1 µg) version to reduce false negative
results due to a supraphysiological stimulus (94, 95). However, in
the setting of the acute phase of TBI a Synacthen test is
inappropriate because of the acute nature of ACTH deficiency,
that would not have time to lead to secondary adrenal
insufficiency. Therefore, patients with TBI would have a
normal response also to the low-dose ACTH stimulation test
(74). Even an extremely accurate test as Insulin Tolerance Test
(ITT) is not feasible for safety concerns in patients with TBI in
the acute phase.
First post-acute phase evaluation should be scheduled 3-6
months after TBI. Thyroid and gonadal axes are frequently
involved, so they should be evaluated. TSH and fT4 are dosed
to confirm or exclude hypothyroidism, while gonadic evaluation
is different between males and females. In men with suspected
hypogonadism LH, FSH, testosterone and PRL levels should be
dosed. In women of reproductive age with menstrual
irregularities is recommended to measure PRL, LH, FSH and
estradiol (E2), while in postmenopausal women gonadotropins
reduction may be sufficient for the diagnosis (78, 83, 93). TheFrontiers in Endocrinology | www.frontiersin.org 8adrenal axis should be re-evaluated measuring morning serum
cortisol and, eventually, using an appropriate stimulation test.
To assess for CDI in patients with polyuria, serum and urine
osmolality should be dosed simultaneously: urine osmolality/
plasma osmolality ratio should be ≥2, after excluding
glycosuria (78).
Somatotropic axis evaluation is recommended at least six
months after TBI because of the possible spontaneous recovery
in the post-acute phase (87). Some Authors proposed to
postpone the evaluation until 1 year after TBI in adults, while
children may require an earlier assessment (83). The diagnosis of
GHD could not be based only on IGF-I levels; even if in patients
with low IGF-I levels and multihormonal deficiency GHD
diagnosis does not require further tests (96), in all other
conditions different dynamic tests are available to confirm the
suspected somatotropic deficiency with a high accuracy (96, 97).
The choice of a test over another is usually based on patient’s
characteristics, availability of secretagogues and center
experience (87). ITT is considered the gold standard and it
evaluates both hypothalamic and pituitary integrity, but it can
be used only after excluding contraindications (i.e. seizure,
cardiac disease) (8, 90). Up to 22% of patients who had TBI
develop seizure disorders, so ITT is often considered not safe in
this setting (98).
The administration of GH Releasing Hormone (GHRH) plus
Arginine (Arg) or GHRH plus GH Releasing Peptide 6 (GHRP-
6) provides a strong stimulus to GH secretion and are considered
safe, so they could be used as a dynamic test for GHD evaluation.
However, they are not useful for GHD of hypothalamic origin
and both GHRH and GHRP-6 are unavailable in many
Countries (96). Glucagon Stimulation Test (GST) is not usually
the first choice for GHD diagnosis. In fact, it could be labored,
requiring a monitoring of at least 3 h, and it could lead to delayed
hypoglycaemia (96). The diagnostic accuracy could be lower in
patients with glucose intolerance (97).
For all GHRH+Arg, GHRH+GHRP-6 and GST different
BMI-related cut-off points are available (99–101). Also for ITT
new BMI-related cut-points have been recently proposed,
allowing to avoid false positive results due to obesity (102).
However, they need further validation.
Lately, Macimorelin test has been proposed for the diagnosis
of adult GHD (97), but data about its use in post-TBI patients are
lacking until now.
An overview of the main stimulation tests for GHD diagnosis
is provided in Table 1.TBI-RELATED GHD: MANAGEMENT AND
OUTCOMES
Rationale for Treatment of Post-Traumatic
GHD
GH is expressed not only at pituitary level but also in many other
organs and tissues, including the central nervous system (CNS)
(103) where it plays an important role in the regulation of cellMarch 2021 | Volume 12 | Article 634415
Gasco et al. TBI and GHD: An Overviewproliferation and survival (104–107). It is well known that GH
plays a role in brain repair, and several preclinical and clinical
studies have demonstrated the positive effects of GH treatment
on neurogenesis in both animals and humans (108, 109).
Moreover, the whole GH system [GH, GH receptor (GHR)
and IGF-I] is acutely and strongly upregulated after brain
injury (110, 111), and specifically associated with stressed
neurons and glia (112–114). However, to date, the role exerted
by GH at CNS level and, in particular, its possible contribution to
the recovery of neurologic injuries remains poorly understood.
GH exerts its beneficial effects on neural repair through
different mechanisms that include regulation of the proliferation,
survival, differentiation and migration of both neural progenitors
and newly formed neurons.
Both in vitro and in vivo studies support the ability of GH to
promote the proliferation of neural precursor. GH treatment
promotes proliferation of both human fetal (115) and adult mice
neural stem cells (NSCs) (106, 116). It has been demonstrated that
peripheral administration of GH is able to induce cell proliferation
in the brain of both normal (117) and hypophysectomized (107)
adult rats (117); moreover, peripheral administration of GH seems
to increase the proliferative response of hippocampal progenitors toFrontiers in Endocrinology | www.frontiersin.org 9kainate-induced injury (118). Despite the main role of GH on the
proliferation of neural precursors, it has been suggested that GH
may actually have a more prominent effect in the regulation of
survival, differentiation, or evenmigration of newly formed neurons
(113). In agreement with the control exerted by GH on cell survival,
GH prevents the apoptotic death of bothmature neurons (119–121)
and primary neurospheres derived from embryonic mouse NSCs
(122). On the other hand, an increased apoptotic death of NSCs is
observed during the treatment with a GHR antagonist (123). Lastly,
GHD has been shown to impair the survival of newborn neurons in
the subgranular zone of adult rat dentate gyrus (124), while elevated
GH levels within the hippocampus reduce apoptosis (125). All these
neuroprotective effects would explain some of the acute
consequences of GH therapy. Several studies support a role for
GH in enhancing neuronal precursors differentiation (126, 127),
while a possible effect of GH on neuronal precursors migration is
less clearly established.
Finally, it cannot be ruled out that GH promotes neurogenesis
and neurorepair, at least in part, through indirect mechanisms
including both the synthesis and the release of IGF-I, epidermal
growth factor (EGF) or erythropoietin (EPO) or changes in
neurotransmitter turnover.TABLE 1 | Main characteristics of GH stimulation tests.
Test ITT GHRH+Arg GHRH+GHRP-6 GST Macimorelin
Drug and dose
administered
Human Regular Insulin 0.1-0.15 UI/
kg iv.
GHRH 1-44 1 µg/kg
iv + Arginine HCl 0.5
g/kg
(max 30 g) infusion.
GHRH 1-44 1 µg/kg iv +
GHRP-6 1 µg/kg iv
Glucagon 1-1.5 mg
im.
Macimorelin 0.5 mg/kg in 1 ml/
kg of water oa.
Sampling and
measurements
GH and glucose at times 0′-30′-45′-
60′-90′
GH at times 30′-45′-
60′
GH at times 0′-15′-30′ GH and glucose at
times
0′-30′-60′-90′-120′-
150′-180′-210′-240′
GH at times 30′-45′-60′-90′
GH cut-points
(µg/L)
- <5 (partial) or <3 (severe).
- ≤3.5 if BMI <25 kg/m2; (*)
- ≤1.3 if BMI 25-30 kg/m2; (*)
- ≤2.2 if BMI >30 kg/m2. (*)
- ≤11.5 if BMI <25
kg/m2;
- ≤8 if BMI 25-30
kg/m2;
- ≤4.2 if BMI >30
kg/m2.
- <10 if BMI ≤35 kg/m2;
- <5 if BMI >35 kg/m2.
- <3 if BMI <25 kg/
m2;
- <1 if BMI ≥25 kg/
m2.
≤2.8
Side Effects - Severe hypoglycaemia;
- Late hypoglycaemia.
Flushing, nausea,
smell and taste
disorders
Flushing Delayed
hypoglycaemia,
nausea, vomiting
Dysgeusia
Contraindications Pregnancy, older age, history of
seizure, history of CAD.
Chronic renal failure. None Severe fasting
hyperglycaemia.
Use of drug that prolong QT.
Pros - Possible simultaneous assessment
of HPA function;
- Evaluation of both hypothalamic
and pituitary integrity.
- Strong selective
stimulus;
- Safe test.
- Strong selective
stimulus;
- Safe test.
Evaluation of both
hypothalamic and
pituitary integrity
- Oral administration;
- High tolerability.
Cons Symptomatic hypoglycaemia (<40
mg/dl) not always achieved in
diabetic patients and obese.
- Not useful for GHD
of hypothalamic
origin;
- GHRH not
commercially
available in every
Country.
- Not useful for GHD of
hypothalamic origin;
- GHRH and GHRP-6 not
commercially available in
every Country.
- Long time needed;
- Labored test;
- Lower accuracy in
patients with glucose
intolerance.
Expensive
Notes Gold standard for GHD diagnosis;
(*) Need further validation of BMI-
dependent cut points.
/// /// Not frequently the
first choice for GHD
diagnosis
Safety and diagnostic
performance not available for
patients <18 and >65 years.March 202ITT, Insulin Tolerance Test; GHRH, Growth Hormone-Releasing Hormone; Arg, Arginine; GST, Glucagon Stimulation Test; iv, intravenous; im, intramuscular; oa, oral administration; GHD,
Growth Hormone Deficiency; BMI, Body Mass Index; CAD, Coronary Artery Disease; HPA, Hypothalamus-Pituitary-Adrenal.1 | Volume 12 | Article 634415
Gasco et al. TBI and GHD: An OverviewIGF-I is the main mediator of GH action and it is essential for
CNS development (128, 129). IGF-I stimulates the proliferation
of neuronal precursors and the survival and differentiation of
both neurons and oligodendrocytes (130). As a result, brain
growth is increased by IGF-I overexpression and reduced as a
consequence of decreased IGF-I levels.
In this context, it must be pointed out that IGF-I has been
shown to be a crucial modulator of CNS activity, including
higher functions like cognition, and to modulate genes involved
in microvascular structure and performance, and synaptic
plasticity (131, 132).
On the other side, EGF has been demonstrated to be a
powerful mitogen capable of inducing neurogenesis both in
basal studies and after experimental injuries (133, 134). Since it
has been shown that GH is able to induce the expression of both
EGF and its receptor (EGFR) and to mediate EGFR activation
(135, 136), it cannot be excluded that the action performed by
GH at CNS level is mediated by these interactions.
EPO and its receptor (EPOR) are other factors involved in
neurogenesis. Both EPO and EPOR have been identified in
numerous areas of the CNS during development, and they are
expressed in several neuronal cells like neurons, astrocytes,
oligodendrocytes, microglia and cerebral endothelial cells,
where EPO activates anti-apoptotic, anti-oxidant and anti-
inflammatory signals and stimulates angiogenesis and
neurogenesis. It is therefore not surprising that EPO can
determine a strong protective effect on neuronal tissue in
experimental models of stroke, cerebral hemorrhage, traumatic
brain injury, and neuroinflammatory and neurodegenerative
diseases (137).
Moreover, it has been shown that the blockade of EPOR in the
CNS leads to impairments in neural cell proliferation and
survival during embryonic development, and in post-stroke
neurogenesis in adult brain, further confirming EPO’s role in
neurogenesis (138, 139). Finally, both in vivo and in vitro studies
show that EPO is able to increase oligodendrogenesis and
remyelination after stroke (140). Since GH induces EPO
release from kidneys (141), it can be assumed that GH
promotes neurogenesis and neurorepair, at least in part,
through indirect mechanisms including EPO mediated effects.
Peripherally, GH is an anabolic hormone that promotes
growth in skeletal and soft tissues (142) through the expression
of GHR at many levels including liver, muscle, bone, and adipose
tissue (143). GH plays an important role in metabolism
stimulating lipolysis, reducing hepatic triglyceride secretion,
activating the nitric oxide system (and so reducing vascular
tone), increasing cardiac performance and exercise capacity,
and promoting longitudinal skeletal growth (142). In patients
with traditional causes of hypopituitarism such as pituitary
tumors, GHD is associated with changes in body composition,
worrisome metabolic dysfunction, reduced bone density, a
significant decrease in QoL, increased cardiovascular risk, and
impaired cardiac function (33, 144). GH replacement therapy
has been shown to be partially beneficial in adults with GHD
(145). However, the evidence of the benefit from GH
replacement therapy in post-traumatic GHD is scant: moreFrontiers in Endocrinology | www.frontiersin.org 10robust data are available about improving cognition and QoL,
but not about all the other parameters.
Literature data on the possible beneficial effects of
recombinant human GH (rhGH) therapy in patients with
GHD post-TBI are currently scarce and fragmented. The
studies available so far are few (14, 146–153), carried out on
small series (147–150, 152–154), extremely variable with respect
to the type of patients considered (severity of TBI, age and sex of
the subjects, presence or absence of other associated hormonal
deficits, time elapsed since TBI), the type of control group
(subjects with GHD from another cause, subjects with GHD
from TBI, subjects with previous TBI but without GHD), the way
in which the condition of GHD is defined (different stimulation
tests, some of which not even recognized for GHD diagnosis by
the international guidelines), the rhGH dose which in some cases
appears supraphysiological (148, 150), the outcomes considered
and the tools used for their detection. Furthermore, the studies in
general have a short duration (3-12 months) and the drop-out is
often high (153). All these factors make the results of every single
study difficult to compare and the results of every individual
experience on a broader case series are scarcely generalizable.
An overview of the main studies investigating GH
replacement therapy in adult post-TBI GHD patients is
provided in Table 2.
Evidence for Treatment of Post-Traumatic
GHD: Cognition
Several studies reported that patients with post-traumatic GHD
have a severe cognitive impairment mainly characterized by
deficit in attention and memory, as well as emotional
problems, and poor verbal learning (7, 33, 85, 86). GHD also
seems to be associated with poor mental health outcomes. The
cognition and quality of life problems experienced by patients
with GHD may be explained by the reduced expression of GH
activity in specific CNS areas involved in memory, learning, and
emotions, like the hippocampus and the limbic system (156–
158). Park et al. showed that patients with GHD after TBI have
decreased cerebral glucose metabolism in specific cortical areas
involved in intellectual function, executive function, and working
memory (88).
It has been demonstrated that in TBI patients the GH
response to stimulation test was negatively correlated to
paranoid ideation and somatization (33). GHD patients have a
moderate to large impairment in each of the cognitive domains
assessed when compared to the matched controls (159) and
patients with post-TBI GHD have a higher risk to achieve poor
cognition outcomes than those with an intact somatotropic axis
after trauma (87). In contrast to all these studies, Pavlovic et al.
did not find significant differences between patients with or
without GHD after brain injury (89). It is well known that GH
replacement therapy in patients with GHD from non-traumatic
causes is of benefit (96, 160). A meta-analysis conducted on
patients with GHD from any cause showed a moderate
improvement in cognitive performance during treatment with
rhGH; the improvement concerned mainly memory and
attention domains (159).March 2021 | Volume 12 | Article 634415
Gasco et al. TBI and GHD: An OverviewTABLE 2 | Studies investigating GH replacement therapy in adult post-TBI GHD patients.
Authors Study design GHD
post TBI
patients
(N)
Control
group (N)
Age of
treated
patients
GHD
testing
rhGH dose§ Duration
of rhGH
treatment
Time
elapsed
from TBI
Parameters analyzed
Kreitschmann-
Andermahr I.
et al. (146)
Retrospective
database
analysis
84 84 GHD
patients
due to
NFPA
Patients:
36.7 ±
10.8 yrs
Controls:
37.3 ±
10.3 yrs
p = NS
ITT
(31 TBI
+39
NFPA);
GHRH
+Arg
(4 TBI+8
NFPA);
GHRH
(16 TBI
+18
NFPA);
Arg
(49 TBI
+31
NFPA)
TBI:
0.41 ± 0.3 mg/day
NFPA:
0.36 ± 0.2 mg/day
12
months*
CO-
GHD:
21.0 ±
8.1 yrs
AO-
GHD:
6.2 ± 9.4
yrs
p =
0.000
BMI; WHR; IGF-I SDS; GH-dose;
fasting lipid profile; QoL-AGHDA
High W.M.
et al. (14)
Open,
prospective,
randomized
study
12
(5 GHD
+7 GHI#)
11 TBI
(3 GHD+8
GHI)
Patients:
36.1 ± 10
yrs
Controls:
39.1 ± 8.5
yrs
p = NS
GST Patients:
0.6 mg/day or
uptitrated to achieve
an IGF-I level in the
upper half of the
normal range
Controls: placebo
12 months Patients:
1.8-33.9
yrs
Controls:
1.9-13.8
yrs
p <
0.058
Muscle biopsy; VO2; muscle strength;
LBM; FM; language; visual/spatial
functioning; upper extremity motor
functioning; information processing
efficiency; working memory/attention;
learning and memory; executive
functioning; intellectual functioning;
emotional functioning
Maric N.P. et
al0 (147)
Open,
prospective
study
4 2 GHD
post TBI
39.3 ± 11
yrs
GHRH
+GHRP-
6
M: 0.3 mg/day;
F: 0.4 mg/day
6 months ≥ 3 yrs Psychiatric assessment: Zung
Depression Inventory and SCL-90-R.
Neuropsychological examination:
MMSE, RAVLT, RCF, TMT, BNT,
WCST
Reimunde P.
et al. (148)
Open,
prospective,
placebo-
controlled
study
11 8 TBI
without
GHD
Patients:
53.4 ±
17.4 yrs
Controls:
47.1 ±
14.6 yrs
GHRH
+Arg
Patients:
1 mg/5 days/week
Controls: placebo
(All subjects received
daily cognitive
rehabilitation)
3 months Patients:
44.6 ±
35.6 yrs
Controls:
46.6 ±
28.8 yrs
Neuropsychological test battery
(WAIS)
Moreau O. K.
et al. (149)
Open,
prospective,
controlled
study
23 27 TBI (15
without
GHD + 9
with partial
GHD° + 3
GHD who
refused
rhGH)
Patients:
37.9 ±
11.7 yrs
Controls:
37.1 ±
12.4 yrs
p = NS
GHRH
+Arg
ITT
0.2-0.6 mg/day 12 months Patients:
7.8 ± 6.6
yrs
Controls:
5.5 ± 6.2
yrs
BMI; Health-related QoL (QOLBI);
RCF; TAP; NRS-R; pADL; iADL
Devesa J.
et al. (150)
Open,
prospective
study
5 8 TBI
without
GHD
Patients:
27.4 ± 4.8
yrs
Controls:
26.3 ±
12.9 yrs
GHRH
+Arg
Patients:
1.0 ± 0.0 mg/5 days/
week resting 15 days
every 2 months
Controls:
0.94 ± 0.1 mg/5 days/
week resting 15 days
every 2 months
(All subjects received
daily rehabilitation
according to the
specific individual
needs)
Patients:
11.2 ± 1.6
months
Controls:
8.9 ± 2.2
months
Patients:
44.1 ±
34.3
months
Controls:
66.8 ±
47.2
months
Cognitive assessment (WAIS,
MMSE); motor assessment (FAC,
Tinetti); swallowing function (FOAMS);
visual function; functional assessment
(MBI); IGF-I
Gardner C. J.
et al. (151)
Retrospective
database
analysis
161 1268 GHD
patients
due to
NFPA
Patients:
42.6 yrs
[40.8; 44.5
yrs]
IGF-I
GHRH
+Arg
Arg
Patients:
0.37 [0.35; 0.40] mg/
day
Controls:
12 months Not
available
BMI; WHR; IGF-I SDS; LBM; FM; BP;
glucose metabolism; GH-dose;
fasting lipid profile;, QoL-AGHDA
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Gasco et al. TBI and GHD: An OverviewA beneficial effect of GH replacement therapy on cognition
has also been reported in post-TBI GHD patients (14, 148, 150).
However, till now, there is not sufficient evidence to support GH
treatment with the aim of improving cognition in post-TBI
GHD patients.
Recovery during a thorough rehabilitation program after TBI
may be positively influenced by normal GH secretion as suggested
by Bondanelli et al. who showed that GH peak during GHRH +
ARG test was an independent predictor of positive outcomes
suggesting that GH replacement therapy may be considered in
post-traumatic GHD patients (161). The improvement in
cognitive function is more significant and appears earlier than
that in motor function; this observation supports the usefulness of
GH replacement therapy in the rehabilitation process of these kindFrontiers in Endocrinology | www.frontiersin.org 12of disabilities (159, 162–164). In general, the improvement during
GH therapy appears to be more marked in patients with worse
cognitive impairment at baseline (149) and it has also been shown
that discontinuation of GH therapy is accompanied by a
worsening of cognitive performance (147).
Although to date the exact mechanism underlying these
effects is not well understood, it cannot be excluded that it
could be based on GH stimulating effect on neurogenesis in
CNS areas related to recent memory like the hippocampal
dentate gyrus. However, stimulation of neurogenesis does not
appear to be the mechanism by which GH therapy improves
other cognitive processes such as attention and concentration. In
this case it has been hypothesized that the effect of GH
replacement therapy is mediated by the action of the hormoneMarch 2021 | Volume 12 | Article 634415TABLE 2 | Continued
Authors Study design GHD
post TBI
patients
(N)
Control
group (N)
Age of
treated
patients
GHD
testing
rhGH dose§ Duration
of rhGH
treatment
Time
elapsed
from TBI
Parameters analyzed
Controls:
53.2 yrs
[52.5;
53.8 yrs]
p < 0.0001
GST
GHRH
ITT
Other
0.33 [0.32; 0.34] mg/
day
p = 0.006
Leonhardt M.
et al. (152)
Open,
prospective
study
4
patients
with
isolated
post-BI
GHD
(only 1
post TBI)
6 TBI
patients
without
hormonal
deficiency
Patients:
49.0 ± 9.8
yrs
Controls:
49.5 ±
13.6 yrs
GHRH
+Arg
0.2-0.5 mg/day 6 months Patients:
25-1024
days
Control:
41-2566
days
QoL (SF-12; EQ-5D; QoLBI; BDI;
PSQI); Cognition (VLMT; test from the
psychological TAP 2.3 test battery of
attention); BMI; Abdominal fat
distribution
Dubiel R.
et al. (153)
Randomized,
prospective,
placebo-
controlled
study
31^ 32 TBI^ Patients:
32.2 ±
15.2 yrs
Controls:
30.1 ±
13.7 yrs
p = NS
Arg^ Patients:
0.4 mg/day up- or
down-titrated to
achieve an IGF-I level
in the upper quintile of
the range for age and
body weight, to a
maximum dose of 1
mg/day
Controls: placebo
12
months▪
Patients:
65.7 ±
30.4
days
Controls:
62.5 ±
41.4
days
p = NS
Glucose metabolism; fasting lipid
profile; free T4; IGF-I; AEs; GOS-E;
DRS; FIM; QoL (SWLS and SF-36);
neuropsychological batteryAEs, adverse event; Arg, arginine: AO-GHD, adulthood onset GHD; BDI, Beck Depression Inventory; BI, brain injury (TBI, aneurysmal subarachoid hemorrhage, ischaemic stroke); BMI,
body mass index; BNT, Boston Naming Test; CO-GHD, childhood onset GHD; DRS, Disability Rating Scale; EQ-5D, EuroQoL; F, females; FAC, Functional Ambulatory Category; FIM,
Functional Independence Measure; FM, fat mass; FOAMS, Functional Outcome Assessment Measure of Swallowing; GHD, Growth hormone deficiency; GHI, Growth hormone
insufficiency; GHRH, Growth Hormone Releasing Hormone; GHRH+Arg, Growth Hormone Releasing Hormone+arginine; GHRH+GHRP-6, Growth Hormone Releasing Hormone
+Growth Hormone Releasing Peptide-6; GOS-E, Glasgow Outcome Scale-Extended; GST, glucagon test; iADL, independence in instrumental activities of daily living; IGF-I SDS, IGF-I
standard deviation score; ITT, insulin tolerance test; LBM, lean body mass; M, males; MBI, Modified Barthel Index; MMSE, Mini Mental State Examination; NFPA, non-functioning pituitary
adenoma; NRS-R, Neurobehavioral Rating Scale-Revised; pADL, independence in personal activities of daily living; PSQI, Pittsburgh Sleep Quality Index; QoL, quality of life; QoL-AGHDA,
Quality of Life-Assessment of Growth Hormone Deficiency in Adults; QOLBI, Quality of Life after Brain Injury; RAVLT, Rey Auditory-Verbal Learning Test; RCF, Rey-Osterrieth Complex
Figure Test; rhGH, recombinant human GH; SCL-90-R, Symptom-check-list; SF-12, 12-Item Short Form Health Survey; SF-36, Short-Form 36; SWLS, Satisfaction with Life Scale; TAP,
Test for Attentional Performance; TBI, traumatic brain injury; Tinetti, balance and gait tests; TMT, Trail Making Test; VLMT, Verbal Learning and Memory Test; VO2, peak oxygen
consumption; WAIS, Wechsler Adults Intelligence Scale; WCST, Wisconsin Card Sorting Test; WHR, waist-hip ratio; yrs, years.
*Data available only from 61 out of 84 TBI patients.
#GHI defined as a GH response to GST greater than 3 ng/ml but less than 8 ng/ml.
§After titration period.
°partial GHD defined as GH peak > 3 ng/ml but < 10 ng/ml to ITT or > 4.0 to 15.6 ng/ml (depending on the patient’s age and BMI) but < the percentile threshold values from ref. (155) in the
GHRH+Arg test.
^Not clear if all patients and controls were GHD subjects: only 24 out of 63 subjects underwent GH stimulation test.
▪Only 16 out of 31 patients and 18 out of 32 controls completed 12 months follow-up.
Gasco et al. TBI and GHD: An Overviewon some neurotransmitter pathways and this might explain the
early responses observed after starting a treatment with rhGH
(116, 118, 148, 150).
Evidence for Treatment of Post-Traumatic
GHD: Metabolic and Cardiovascular
Risk Factors
Regardless of pathogenesis, GHD is associated with adverse
effects on body composition, alterations in glucose and lipids
metabolism, reduced physical and cardiovascular performance
(165); all these alterations are thought to be the cause of the
incresed cardiovascular mortality observed in hypopituitaric
patients (166–168). A systematic review showed a small but
significant improvement on lean and fat body mass, low-density
lipoprotein-(LDL) and total cholesterol, and diastolic blood
pressure in GHD adults during GH replacemente therapy
(169). In contrast, plasma glucose and insulin levels were
increased during GH therapy (169). However, improvement in
hard outcomes, such as reductions in cardiovascular events and
mortality, has yet to be demonstrated (96, 170).
Several studies argue metabolic disorders in patients with
post-traumatic GHD. In patients with post-TBI hypopituitarism,
mainly GHD, high LDL and total cholesterol levels, waist
circumference, and total fat mass have been showed (19).
Treatment of these patients has shown variable results. In one
observational study, weight or waist to hip ratio did not change
in post-traumatic GHD patients treated with rhGH for a year
(146), while in another study there was an improvement in blood
pressure, total and LDL cholesterol after 1-year treatment in
patients with GHD post TBI (151). A case study of two patients
with GHD secondary to sport-related TBI showed some
improvement in lipid profile and body composition after a 6-
month treatment with rhGH (171).
Patients with TBI have been found to have a reduced aerobic
capacity, a well-established measure of physical endurance and
fatigue resistance, which may further delay or hinder the
rehabilitative process (81). In particular, patients with TBI and
a normal GH axis show suboptimal aerobic capacity and those
with GHD performed even worse (81). Although GH treatment
seems to improve skeletal muscle mass in patients with GHD
from non-traumatic causes, data available are not so convincing
in post-traumatic GHD patients and the improvement, if any,
seems to concern only male patients with TBI and GHD (172). A
case study of one patient showed an improvement in muscle
force production, body composition, and aerobic capacity after
treatment with rhGH for 12 months (173).
Evidence for Treatment of Post-Traumatic
GHD: Bone Health
A higher risk of osteopenia, osteoporosis, and vertebral fractures
is observed in hypopituitaric patients adequately replaced with
glucocorticoids and thyroid hormones (174) suggesting a
fundamental role of both GH and gonadotropins secretion
disturbances in the pathogenesis of the reduced bone health
observed in these patients. Apparently, in GHD patients there is
no difference related to gender and age. GH replacement therapyFrontiers in Endocrinology | www.frontiersin.org 13increases bone mineral density (BMD) (175, 176) and seems to
mitigate the increased fracture risk observed in GHD patients
(174), but specific data for skeletal outcomes in TBI induced
GHD are lacking.
Evidence for Treatment of Post-Traumatic
GHD: QoL
Regardless of the cause, GH is characterized by a compromised
QoL (177, 178). Patients with post-traumatic GHD are more
likely to be depressed and with a poorer QoL than those with
GHD due to other causes (85, 160). Interestingly, patients with
post-TBI GHD, when compared to those with GHD secondary to
NFPA, seemed to have a less severe GHD at biochemical level,
but worse QoL scores (151). In particular, domains of physical
health, energy and fatigue, emotional well-being, pain, and
general health seem to be affected (85). This perceived poor
QoL would negatively impact on rehabilitation after TBI. In
general, the treatment of GHD of any cause seems to improve
QoL as measured by the QoL-AGHDA (Quality of Life
Assessment of Growth Hormone Deficiency in Adults) score
and other evaluation tools (179). The QoL improvement is
higher in post-traumatic GHD patients than in patients with
GHD due to NFPA, especially in the domains of socialization,
self-confidence, and tenseness (151). The observed improvement
was maintained for a long time, up to eight years, and always
based on continuation of treatment.CONCLUSIONS
TBI is one of the leading causes of disability and mortality
affecting many people each year and resulting in a serious
burden of devastating health consequences. TBI may lead to
transient or permanent pituitary insufficiency. After the initial
primary injury, secondary mechanisms that involve an interplay
of ischemia, inflammation, and cytotoxicity seem to result in
hypopituitarism that causes adverse changes in body
composition, worrisome metabolic dysfunction, decreased bone
density, and a significant reduced QoL. GHD, the most common
pituitary hormone deficiency after TBI, is associated with adverse
sequelae, which may impair recovery and rehabilitation. The
poor outcomes that are seen with long standing GHD in post TBI
patients could be improved by treatment with rhGH, but
literature data on the possible beneficial effects of GH
replacement therapy in post-TBI GHD patients are currently
scarce and fragmented. More studies are needed to further
characterize the post-TBI GHD syndrome with the purpose of
establishing appropriate standards of care.AUTHOR CONTRIBUTIONS
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